The relation between free serotonin in plasma, serotonin in platelets, and the type of serotonin transporter in carcinoid tumor patients, patients using SSRI, and healthy controls.
Recruiting
- Conditions
- In English: carcinoid tumor, SSRI, selective serotonin reuptake inhibitor, serotonin, plasma, platelets, serotonin transporter.Nederlands: carcinoïd tumor, SSRI, selectieve serotonine heropname remmers, serotonine, plasma, bloedplaatjes, serotonine transporter
- Registration Number
- NL-OMON24450
- Lead Sponsor
- niversity Medical Center Groningen
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 105
Inclusion Criteria
Ethics:
1. Approval of the METC UMCG;
Exclusion Criteria
1. The use of medication that interferes with the serotonin metabolism or serotonin reuptake (exception: use of SSRI in patients with depression/anxiety disorder), for example aspirin, psychofarmaca (other than SSRI (TCA, MAO-inhibitors, mirtazapine, bupropion, venlafaxine, duloxetine), anxiolytics, antipsychotics, and anticonvulsants;
2. Drug abuse (8 weeks prior to inclusion);
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Analyzing whether there is a difference in the concentration dopamine and serotonin in the plasma and platelets of carcinoid tumor patients, patients using SSRI, and healthy controls.
- Secondary Outcome Measures
Name Time Method Analyzing whether the concentration free serotonin in plasma, and the ratio free serotonin/serotonin in platelets is determined by the genotype of the serotonin transporter.